1. Home
  2. Press release
Oct, 15 2019 21:24 JST

Source: Eisai

Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China


TOKYO, Oct, 15 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. Fycompa was designated for Priority Review by the NMPA due to its significant clinical benefits compared to existing treatments, and was approved in about 12 months since the submission in September 2018.

In China, it is estimated that there are approximately 9 million patients with epilepsy, approximately 60% of whom being affected by partial-onset seizures. About 40% patients with partial-onset seizures require adjunctive treatment.1 As approximately 30% of patients with epilepsy are unable to control their seizures with currently available AEDs,2 this is a disease with significant unmet medical needs.

Fycompa is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. Administered orally once-daily, it is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes.

Fycompa has been approved in over 60 countries around the world as an adjunctive treatment for partial- onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older. In addition, Fycompa has been approved in over 55 countries as an adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. In the United States, Fycompa is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older.

Eisai considers neurology including epilepsy, a therapeutic area of focus. With this approval of Fycompa in China, Eisai pursues our mission to provide "seizure freedom" to a greater number of patients with epilepsy across the world living. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.


Contact:
Eisai Co., Ltd. 
Public Relations Department
+81-(0)3-3817-5120
Source: Eisai
Sectors: HealthCare

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai's Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan
November 20 2019 13:01 JST
 
Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
November 05 2019 09:02 JST
 
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 23 2019 10:13 JST
 
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
October 01 2019 10:46 JST
 
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
September 30 2019 11:06 JST
 
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
September 26 2019 13:21 JST
 
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
September 26 2019 13:08 JST
 
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
September 24 2019 09:01 JST
 
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
September 20 2019 15:13 JST
 
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
September 20 2019 08:40 JST
 
More Press release >>

Latest Press Release


All-New Mazda3 Named China Car of the Year 2020
Nov 22, 2019 13:30 JST

World Premiere of Lexus' First EV, the UX 300e
Nov 22, 2019 11:55 JST

All-New Mazda3 Named Thailand Car of the Year 2019
Nov 21, 2019 16:22 JST

Toyota Refines Rehabilitation Assist Robot and Launches New Welwalk WW-2000
Nov 21, 2019 14:33 JST

Sojitz, NTT Com, NEC, NEC Networks & System Integration to Upgrade Communications Infrastructure in Myanmar
Nov 20, 2019 17:33 JST

Toyota Revs Up Lineup with New 302-Horsepower RAV4 Prime
Nov 20, 2019 14:48 JST

Mayo Clinic, Hitachi to Build First, Next-Generation, Carbon Ion Therapy Treatment Facility in North America
Nov 20, 2019 14:34 JST

Eisai's Equfina 50mg Tablets (Safinamide Mesilate) Launched in Japan
Nov 20, 2019 14:01 JST

The Stunning Lexus LC 500 Convertible Makes its Global Debut at the 2019 Los Angeles Auto Show
Nov 20, 2019 11:06 JST

Hitachi and Cambridge Renew 30 Year Research Partnership
Nov 19, 2019 13:01 JST

Showa Denko to License Vinyl Acetate Monomer Technology to Shenghong Refining Petrochemical, China
Nov 19, 2019 12:30 JST

Fujitsu and RIKEN Claim 1st Place in the Green500 with Prototype of Fugaku Supercomputer
Nov 19, 2019 09:06 JST

Toyota Mobility Foundation Joins Public, Private and Academic Parties to Launch the Rama4 Project to Ease Traffic Congestion in Bangkok
Nov 18, 2019 17:30 JST

Mazda3 Named 2019 Women's World Car of the Year
Nov 18, 2019 15:39 JST

MITSUBISHI MOTORS Launched Restyled Mirage and Attrage Compact Models in Thailand
Nov 18, 2019 12:24 JST

Hitachi SEM Receives Order for Around 5,600 Distribution Transformers from the Republic of the Union of Myanmar's Ministry of Electricity and Energy
Nov 18, 2019 11:50 JST

Fujitsu Launches "AuthConductor V2" to Take Biometric Authentication to the Next Level
Nov 18, 2019 11:20 JST

MITSUBISHI MOTORS' eK X & eK Wagon Kei Cars Win RJC Car of the Year 2020
Nov 13, 2019 19:39 JST

MHI Aero Engines Makes First Shipment of Domestically Assembled Pratt & Whitney GTF PW1200G Engine for the Mitsubishi SpaceJet
Nov 13, 2019 16:01 JST

Fujitsu Launches New PRIMEHPC Supercomputers Using Fugaku Technology
Nov 13, 2019 10:37 JST
 More Latest Release >>